Nanoparticles for drug delivery in Parkinson’s disease

Jonathan Baskin*, June Evelyn Jeon, Simon J. G. Lewis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

Although effective symptomatic treatments for Parkinson’s disease (PD) have been available for some time, efficient and well-controlled drug delivery to the brain has proven to be challenging. The emergence of nanotechnology has created new opportunities not only for improving the pharmacokinetics of conventional therapies but also for developing novel treatment approaches and disease modifying therapies. Several exciting strategies including drug carrier nanoparticles targeting specific intracellular pathways and structural reconformation of tangled proteins as well as introducing reprogramming genes have already shown promise and are likely to deliver more tailored approaches to the treatment of PD in the future. This paper reviews the role of nanoparticles in PD including a discussion of both their composition and functional capacity as well as their potential to deliver better therapeutic agents.

Original languageEnglish
Pages (from-to)1981-1994
Number of pages14
JournalJournal of Neurology
Volume268
Issue number5
DOIs
Publication statusPublished - May 2021
Externally publishedYes

Keywords

  • Blood–brain barrier
  • Inorganic nanoparticles
  • Lipid-based nanoparticles
  • Nanoparticles
  • Parkinson’s disease
  • Polymeric nanoparticles
  • Targeted delivery

Fingerprint

Dive into the research topics of 'Nanoparticles for drug delivery in Parkinson’s disease'. Together they form a unique fingerprint.

Cite this